We are live on ! Find out more
IOBT

IO Biotech
IOBT

Delisted

IOBT was delisted on the 6th of April, 2026.

Back to rankings

20 hedge funds and large institutions have $92.6M invested in IO Biotech in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

52.18% more ownership

Funds ownership: 0% → 52.18% (+52%)

Holders
20
Holders Change
+20
Holders Change %
–
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$31.7M
2
VC
Vivo Capital
California
+$29.1M
3
ACA
Avoro Capital Advisors
New York
+$19.9M
4
RCM
RA Capital Management
Massachusetts
+$17.9M
5
PHS
PFM Health Sciences
California
+$13.2M

Top Sellers

No sellers this quarter

IOBT Hedge Fund Activity: Q4 2021 in Review

20 of the 6,520 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q4 2021, worth a combined $92.6M.

Buyers outnumbered sellers: 20 funds opened new IOBT positions and 0 closed out — a net gain of 20 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $31.7M.

  • 20 institutional investors held IO Biotech (IOBT) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $92.6M of IO Biotech stock for Q4 2021.
  • 20 funds opened new IO Biotech positions in Q4 2021 and 0 closed out, a net change of +20 holders.
  • The largest IO Biotech buyer in Q4 2021 was Novo Holdings A/S, an estimated $31.7M added.

Based on aggregated 13F filings for Q4 2021.